Focus: KSQ Therapeutics is a CRISPR-based drug discovery biotech founded in 2018, focused on gene therapy and oncology. The company is a small, early-stage public entity headquartered in Lexington, MA with fewer than 50 employees.
Profile data last refreshed 3h ago · AI intelligence enriched 3d ago
No open roles listed right now. Follow KSQ Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from KSQ Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for KSQ Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
TIL Therapy Clinical Trial Pipeline Appears Robust With 17+ - GlobeNewswire
TIL Therapy Clinical Trial Pipeline Appears Robust With 17+ GlobeNewswire
DUB Inhibitors Market to Witness Strong Expansion Across 7MM by 2040 Driven by the Launch of Novel Therapeutics | DelveInsight - PR Newswire
DUB Inhibitors Market to Witness Strong Expansion Across 7MM by 2040 Driven by the Launch of Novel Therapeutics | DelveInsight PR Newswire
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo